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transformation, tumor progression, invasion, metastasis, 
angiogenesis promotion, escape from immune surveillance, 
and drug resistance, thereby facilitating disease progres-
sion. The presence of tumor-derived ectosomes in body flu-
ids such as the blood and urine of cancer patients makes 
them potentially useful prognostic and predictive biomark-
ers. Tumor-derived ectosomes also offer possible targets for 
multiple therapeutic strategies.
Keywords Cancer · Ectosomes · Immunosuppression · 
Intracellular communication · Multidrug resistance · Tumor 
microenvironment
Abbreviations
ADAMT  Adamalysin metalloproteinase with disinteg-
rin and thrombospondin domains
ARF6  ADP-ribosylation factor 6
BCRP  Breast cancer resistance protein
CSF  Cerebrospinal fluid
ECM  Extracellular matrix
EGFR  Epidermal growth factor receptor
EMMPRIN  Extracellular matrix metalloproteinase 
inducer
EMT  Endothelial to mesenchymal transition
ERK  Extracellular signal-regulated kinase
EV  Extracellular vesicle
FAK  Focal adhesion kinase
FN  Fibronectin
HGF  Hepatocyte growth factor
LIMK  LIM kinase
MDR  Multidrug resistance
MLCK  Myosin light-chain kinase
MMP  Matrix metalloproteinase
MRP1  Multidrug resistance-associated protein 1
PAD  Peptidylarginine deiminase
Abstract Ectosomes are small heterogeneous membrane 
vesicles generated by budding from the plasma membrane 
in a variety of cell types and, more frequently, in tumor 
cells. They are shed into the extracellular space and are 
proposed as a novel form of intracellular communication in 
which information is transmitted from the originating cell 
to recipient cells without direct cell-to-cell contact. This 
review focuses on a single population of extracellular vesi-
cles—ectosomes. We summarize recent studies of tumor-
derived ectosomes which examine their biogenesis and pro-
tein cargo, and their influence on different aspects of cancer 
progression. We discuss possible clinical implications 
involving ectosomes as potential biomarkers, diagnostic 
tools and treatment targets in oncology. The unique com-
position of the molecules (cargo) that ectosomes carry, and 
their functional role, depends largely on the state of their 
originating cell. Through horizontal transfer of a variety of 
biologically active molecules (including proteins, lipids and 
nucleic acids) between donor and recipient cells, tumor-
derived ectosomes may play functional roles in oncogenic 
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PE  Phosphatidylethanolamine
PMV  Platelet-derived microvesicle
PS  Phosphatidylserine
PSGL  P-selectin glycoprotein ligand
ROCK  Rho-associated coiled coil containing protein 
kinase
ROS  Reactive oxygen species
TF  Tissue factor
TGF-β  Transforming growth factor β
TNF-α  Tumor necrosis factor α
TMV  Tumor-derived microvesicle
tTG  Tissue transglutaminase
uPA  Urokinase plasminogen activator
VEGF  Vascular epithelium growth factor
Introduction
Cancer development and progression are multistep pro-
cesses in which a series of changes in the tumor micro-
environment and in intercellular communication occur. 
Those highly specific alterations are driven mainly by 
endogenous molecular factors with proven oncogenic 
potential. Most bioactive molecules involved in carcino-
genesis are directly secreted and act in an auto-, para- or 
endocrine manner, but another mechanism of their deliv-
ery to target cells has also been described. A variety of 
cell types, including cancer cells, are known to release 
extracellular vesicles (EVs)—small, membrane-enclosed 
particles which can mediate the transfer of different sign-
aling factors, structural proteins, nucleic acids or lipids 
[1]. Following their in  vivo release to the intercellular 
space, EVs typically are detected in a wide spectrum 
of body fluids such as blood (plasma or serum), urine, 
cerebrospinal fluid (CSF), bile, ascites, saliva, amniotic 
fluid, milk or semen; they can also be isolated in  vitro 
from conditioned media of cultured cells. Such accessi-
bility contributes to their prognostic, diagnostic and ther-
apeutic value for particular health conditions [2].
Over the years, successive studies have revealed striking 
diversity within EV populations. Across this diversity they 
can be classified into several distinct populations based on 
their size, density, cellular origin, release mechanism and 
marker proteins [3]. In the EV-related nomenclature, one 
dominant naming convention of definitions has emerged 
recently [4–6], as outlined below.
Ectosomes represent a fairly heterogeneous population 
of vesicles ranging in diameter from 0.1 to 1 µm (Fig. 1a). 
As a result of loss of calcium-dependent membrane phos-
pholipid asymmetry and rearrangement of the cytoskeleton, 
ectosomes are formed by outward membrane budding and 
then are shed from the cell surface [1, 3, 7, 8]. Another 
population of smaller (30–100  nm) EVs called exosomes 
can be released by fusion of multivesicular bodies with 
the cell membrane, followed by exocytosis (Fig. 1b) [1, 3, 
7, 8]. Finally, cells undergoing apoptosis and fragmenta-
tion also release vesicles formed by membrane protrusion. 
Unlike ectosomes, however, apoptotic bodies may contain 
cytosolic organelles or nuclear fragments, and they are 
considerably larger (up to 5 µm) (Fig.  1c) [3, 8]. Table 1 
briefly characterizes these three populations of EV. Table 2 
gives examples of molecular markers associated with ecto-
somes. Recently the existence of a new type of EVs termed 
sphereosomes has been postulated [9]. The presence of 
these structures, between 40 and 125 nm in size, was first 
described in gastrointestinal stromal tumor cells. Sphere-
osomes are believed to be formed through a newly found 
mechanism of shedding from multivesicular spheres.
Fig. 1  Representative images of extracellular vesicles released from 
tumor cells. a Exosomes from urine of diabetic patients (transmis-
sion electron microscopy, TEM), b ectosomes from human mela-
noma WM1205Lu cells (TEM), c apoptotic bodies from human acute 
lymphoblastic leukemia MOLT-4 cells (May-Grűnwald-Giemsa stain-
ing)
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Table 1  Comparison of three types of EVs: exosomes, ectosomes and apoptotic bodies
Vesicle population
Exosomes Ectosomes Apoptotic bodies
Size in diameter 30–100 nm 100–1000 nm 1000–4000 nm
Appearance Homogeneous Heterogeneous Heterogeneous
Sedimentation 100,000–120,000×g 16,000–20,000×g 5000–16,000×g
Filtration 20–200 nm >200 nm >1000 nm
Site of generation Multivesicular bodies (MVBs) Plasma membrane Cells undergoing apoptosis
Type of generation Constitutive Regulated Regulated
Mechanism of generation Exocytosis of multivesicular bodies Budding from plasma membrane Cell shrinkage and death
Mechanism of sorting Ceramide-dependent Unknown N/A
Intracellular storage Yes No No




Lipid composition Cholesterol, Ceramide Phosphatidyserine,
Cholesterol
Phosphatidyserine
Genetical information Non coding RNA,
micro RNA
mRNA, micro RNA mRNA, micro RNA,
DNA
Intact organelles No No Yes
Anexin V binding Poor Strong Strong
Impact on the immune system Immunostimulators Immunosuppressors Immunosuppressors
Table 2  Molecular markers of ectosomes
Biomarker class Name Functions References
Membrane associated proteins Tissue factor (TF) Thrombus formation, activation of cancer stem cells and angio-
genesis
[10, 11]
Integrins β1 integrin—cell adhesion,
CD41 (GPIIb/IIIa, αIIbβ3)—platelet aggregation and adhesion
[12, 13]
ARF6 Remodeling of membrane lipids, regulation of ectosome release [14, 15]
Lineage markers CD14 (monocytes), CD61 (platelets), CD62e (endothelium), 
CD66b (granulocytes), CD45 (leukocytes),
CD4 (Th lymphocytes), CD8 (Ts lymphocytes), CD20 (B lym-
phocytes), Glycophorin A (erythrocytes)
[16]
EGFR Signal transduction [17, 18]
VAMP3 v-SNARE [14]
LAMP-1 Decreasing NK cells anti-tumor response [19]
Membrane associated lipids Flotillin-1 Lipid raft molecule [20]
Phosphatidylserine (PS) Membrane phospholipid [21]
Sphingomyelin (SM) Membrane phospholipid [22]
Soluble Proteases (MMP2, MMP9, uPA) Degradation of extracellular matrix [12, 23–26]
CD147/basigin/EMMPRIN Extracellular matrix metalloproteinases activator [27]
VEGF Proangiogenic factor [28]
IL-1β Inflammation cytokine [29]
Cytoskeleton associated Actin Not defined [30]
Myosin Pinching of vesicle neck during release of ectosome [15]
Ezrin Multi drug-resistance [31, 32]
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It is well established that EVs can be released under both 
physiological and pathological conditions. The particular 
function of an EV arises from the cargo it carries, which is 
highly dependent on the cell type from which a given EV 
originates [33]. Examples of ectosome cargo are shown in 
Fig. 2. The biological processes that may be controlled or 
modulated by vesicular content include coagulation, local 
inflammation, cell differentiation, vascular senescence and 
remodeling [4, 5, 7, 34, 35]. Cancer cells are known to 
release increased amounts of EVs, often described under 
a collective name: tumor-derived microvesicles (TMVs). 
The specific cargo that is horizontally transferred within a 
TMV affects a variety of cellular events during the respec-
tive stages of cancer progression. TMVs contain molecules 
directly stimulating invasion, metastasis and angiogenesis. 
Other components promote the acquisition of an aggressive 
phenotype or influence changes in the tumor microenviron-
ment within the primary site and metastatic niche. TMVs 
may also facilitate transfer of the commonly used chemo-
therapeutics out of the cell, thereby contributing to multi-
drug resistance. Finally, fusion of TMVs with immune 
cells often leads to inhibition or alteration of the immune 
response to cancer cells [1, 5, 36].
Our knowledge of the role of EVs in carcinogenesis is 
increasing vastly. This review focuses on a single popula-
tion of EVs—ectosomes. We give the main points of recent 
studies of tumor-derived ectosomes which examine their 
biogenesis, proteome cargo, and the influence of that cargo 
on the different aspects of cancer progression. We discuss 
the clinical implications of the potential use of ectosome 
proteomes as biomarkers, diagnostic tools and treatment 
targets in oncology.
Biogenesis of ectosomes
Better knowledge of EV biogenesis will be critical to an 
understanding of their role in intercellular communication, 
and eventually may allow this process to be regulated in dif-
ferent cell types, including cancer cells. Recent reports sug-
gest that several types of EVs can be released from a single 
donor cell [29]. The formation of EVs entails the accumu-
lation of their components in particular domains within the 
membranes of origin, which subsequently undergo budding 
(Fig. 3). While this initial assembly mechanism is similar 
in exosomes and ectosomes, the processes by which these 
two populations are released to the intercellular space differ 
significantly. In both cases the release of EVs is highly reg-
ulated and proceeds under the control of numerous molecu-
lar modulators [1, 7].
Since Wolf’s first description of ectosome-like parti-
cles originated from platelets [38], numerous studies have 
investigated the possible mechanisms of ectosome forma-
tion. Over the years it has become obvious that, unlike in 
exosomes, the release of ectosomes does not require exocy-
tosis. It involves the formation of outward buds in specific 
regions of the cell membrane, followed by direct shedding 
Fig. 2  Examples of ectosome 
cargo. ARF6: ADP-ribosylation 
factor 6, CD40: cluster of differ-
entiation 40, EGFR: epidermal 
growth factor receptor, EMM-
PRIN: extracellular matrix 
metalloproteinase inducer, 
IL-1β: interleukin 1β, LAMP-1: 
lysosomal-associated membrane 
protein 1, MMP: matrix metal-
loproteinase, uPA: urokinase 
plasminogen activator, VAMP-
3: vesicle-associated membrane 
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and immediate release of the vesicle to the intercellular 
space [39]. These processes are initiated mainly via activa-
tion of a given cell by different agonists (e.g. ATP, growth 
factors, cytokines) and subsequently an increase in the level 
of intracellular  Ca2+. Once additional  Ca2+ is released from 
the endoplasmic reticulum, the cell membrane undergoes 
significant molecular rearrangement at the sites of ecto-
some origin, including changes in lipid and protein compo-
sition as well as in cytoskeleton structure [40].
Free calcium ions act as cytosolic secondary messen-
gers, leading to the recruitment and activation/inhibition 
of several enzymes engaged in maintaining membrane 
asymmetry. Prior to ectosome release, phosphatidylserine 
(PS) and phosphatidylethanolamine (PE) are exposed on 
the outer leaflet of the cell membrane as a result of flop-
pase and scramblase activation in response to strong 
 Ca2+-mobilizing agents. At the same time, another trans-
locase–flippase—is inhibited, thus preventing relocation 
of the aforementioned phospholipids [1, 3, 39]. A defi-
ciency of  Ca2+-dependent phospholipid scrambling activ-
ity, caused by mutation of the transmembrane protein anoc-
tamin-6 gene (ANO6, also known as TMEM16F), reduces 
platelet activation and PS exposure on platelets and other 
cells, and it up-regulates a number of cytoskeleton, lyso-
some/peroxisome-related and phospholipid regulatory 
proteins [41]. PS-positive ectosomes can be distinguished 
Fig. 3  Mechanisms responsible for ectosome blebbing and release. 
Ectosomes are generated by outward budding and fusion of the 
plasma membrane, but their membrane composition is distinct from 
that of parental cells. Alterations of phospholipid symmetry are gov-
erned by aminophospholipid translocases (flippase and floppase) and 
 Ca2+-dependent scramblase. Ectosomes are enriched in cholesterol, 
whereas phosphatidylserine (PS) is exposed on the extracellular leaf-
let of shed ectosomes. Cytoskeletal reorganization upon ectosome 
release is induced by calpain and gelsolin, although alternative mech-
anisms in cancer cells have been described, including RhoA [37] or 
ARF6 [14, 15] and their effectors. ARF6: ADP-ribosylation factor 
6, ERK: extracellular signal-regulated kinase, LIMK: LIM domain 
kinase, MLCK: myosin light chain kinase, RhoA: Ras homolog gene 
family member A, ROCK: Rho-associated protein kinase
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easily from other circulating EVs with the use of flow 
cytometry by annexin V or lactadherin binding [21, 34, 
42]. Increased  Ca2+ levels may also facilitate degradation 
of the cytoskeleton structure and subsequent vesiculation 
by activating calcium-dependant proteases such as calpain 
and gelsolin [3]. Recent studies have identified RhoA, a 
member of the Ras protein superfamily of small GTPases, 
another regulator of ectosome release. By acting through 
its downstream effectors—a Rho-associated coiled-coil 
containing protein kinase (ROCK), LIM kinase (LIMK) 
and coffilin-RhoA altered the structure of actin–myosin 
filaments, leading to increased ectosome release by differ-
ent cancer cell lines [37]. The release of ectosomes from 
invasive cells can be regulated by a GTP-binding protein, 
ARF6 [14, 15]. By activating extracellular signal-regulated 
kinases (ERK) and myosin light-chain kinase (MLCK), 
ARF6 regulates actin polymerization and phosphorylation 
of myosin light chains, leading to ectosome release [14].
Biological role of ectosomes in carcinogenesis
The biological and clinical significance of ectosome secre-
tion has been a subject of sustained research. The majority 
of evidence for the role of ectosomes in cancer is based on 
correlative studies in clinical and preclinical settings and 
on experiments done in vitro. In the first report confirming 
the release of ectosomes by cancer cells, from 1978, they 
were identified in cultures of spleen nodules and lymph 
nodes from a patient with Hodgkin lymphoma [43]. Soon 
thereafter, different melanoma cell lines were shown to 
release ectosomes [44, 45] which displayed the ability to 
boost metastatic potential when fused with less invasive 
tumor cells [44].
The particular effects exerted by ectosomes during can-
cer progression depend on their interactions with recipi-
ent cells. As described in a recent review, binding of ecto-
somes is most likely determined by different adhesion 
molecules, such as integrins [2]. Upon binding, ectosomes 
stimulate target cells by delivering surface receptors, or by 
directly inducing receptor-mediated signal transduction via 
transported ligands, or by delivering bioactive molecules 
(proteins, lipids, nucleic acids) after fusion with the cell 
membrane or after endocytosis [33, 46]. Regardless of the 
mechanism, an ectosomal cargo can modulate essential 
processes in associated cancer cells, as well as functions 
of fibroblasts [47], endothelial cells [48] and immune cells 
[49]. The described disruption of homeostasis within the 
tumor microenvironment, changes in the structure of the 
extracellular matrix (ECM) and transfer of oncogenic phe-
notypes all testify to the participation of ectosome release 
in different stages of cancer progression.
Transfer of oncogenic phenotypes
Cancer development was long considered a consequence of 
multistep mutations of genetic material. Nowadays there is 
a shift from those strictly genocentric explanations for the 
transformation from normal to malignant cells, towards epi-
genetic and other non-genetic interpretations. Non-genetic 
mechanisms of phenotypic transformation may involve the 
transfer, via ectosomes, of membrane receptors for growth 
factors, RNA molecules or even lipids [50]. For instance, 
the oncogenic mutant of an epidermal growth factor recep-
tor (EGFRvIII) was shown to be horizontally transferred 
within ectosomes released by glioma cells and taken up 
by a non-invasive population of tumor cells in  vitro [17, 
18]. Cells that acquired EGFRvIII exhibited activation of 
the MAPK and Akt signaling pathways, along with altered 
expression of genes regulating cell survival (BclxL) and 
proliferation (p27), resulting in a series of morphological 
changes and stimulation of anchorage-independent growth 
[17]. Ectosomes containing mRNA for EGFRvIII isolated 
from human glioblastoma sections consistently stimulated 
in vitro proliferation of malignant glioma cells (U87) [48].
Other findings highlight the role of ectosomes in the 
transformation of normal cells within the tumor microen-
vironment. Antonyak et  al. [47] demonstrated that ecto-
somes released by breast cancer and glioblastoma cell lines 
(MDAMB231 and U87) contain tissue transglutaminase 
(tTG) and its tTG-binding partner and cross-linking sub-
strate, fibronectin (FN). Once transferred to the recipient 
fibroblasts via ectosomes, tTG and FN acted cooperatively 
to induce their transformation by activating mitogenic sign-
aling (phosphorylation of FAK and ERK kinases), leading 
to increased cell survival and aberrant growth [47].
Tumor cell invasion and metastasis
The metastatic cascade begins with local invasion of pri-
mary tumor cells within the surrounding tissue. Once the 
cells pass the barrier of the basement membrane, they are 
able to penetrate the lumen of the blood vessels (intrava-
sation) and then travel with the blood stream to predeter-
mined metastatic sites. Subsequent migration of tumor cells 
from the blood to the target tissue (extravasation) starts the 
process of secondary tumor growth. The results of numer-
ous studies support the suggestion that various molecules 
of the ectosomal cargo play a significant role at each stage 
of the metastatic cascade [36].
The invasive and migratory properties of tumor cells are 
highly dependent on the activity of different proteases such 
as matrix metalloproteinases (MMPs). By degrading par-
ticular components of the ECM, this group of enzymes pro-
motes the mobility of migrating cells and creates a path of 
less resistance. MMPs are also responsible for proteolysis 
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within the basement membrane, which allows tumor cells 
to penetrate the lumen of blood and lymphatic vessels 
and metastasize [36]. The presence as well as the proteo-
lytic activity of MMP-2 and MMP-9 have been identified 
in ectosomes released in  vitro by fibrosarcoma (HT1080) 
[51], ovarian (CABA1, A2780) [23, 28], breast (8701-BC) 
[12], prostate (PC3, LnCaP) [24, 25] and lung (HTB 177, 
CCL 185) [26] cancer cell lines.
It is well established that the activity of MMPs is regu-
lated at several levels, including transcription, enzyme acti-
vation/inhibition, complex formation, and compartmentali-
zation [52]. Supporting this, studies using fibrosarcoma and 
prostate cancer cell lines showed that urokinase plasmino-
gen activator (uPA) is associated with ectosomes released 
in  vitro. Addition of plasminogen to the ectosomal frac-
tion resulted in activation of zymogens, indicating a role 
of the urokinase-plasmin system in MMP-2 and MMP-9 
activation [24, 25, 51]. The activity of vesicle-associated 
proteases may also be influenced by the pH of the tumor 
microenvironment. In solid tumors the extracellular pH is 
acidic due to elevated anaerobic glycolysis and impaired 
clearance of metabolic waste products. It has been found 
that low pH may promote the invasiveness of ectosomes 
by cathepsin B-mediated activation of gelatinases. Expos-
ing vesicles released by ovarian cancer cells (CABA1) 
to acidic medium increased MMP-2 and MMP-9 activi-
ties; this effect was abolished by the specific inhibitor of 
cystein protease or by silenced expression of cathepsin B 
in CABA1 cells [53]. CD147/extracellular MMP inducer 
(EMMPRIN), a membrane glycoprotein, may also be 
involved in the progression of malignancies via regulation 
of the expression of MMPs in tumor cells. CD147/EMM-
PRIN-bearing ectosomes derived from breast cancer cell 
lines (MCF-7, SK-BR-3, MDA-MB231) induced invasion 
of both autologous and heterologous cells. This effect was 
not mediated by matrix metalloproteinases, which were 
absent in the released ectosomes, but rather by activation of 
the p38/MAPK signaling pathway in tumor cells [27].
Proteolysis within the ECM can also result from the 
activity of adamalysin metalloproteinases with disintegrin 
and thrombospondin domains (ADAMTSs). Ectosomes 
shed by oligodendroglioma cells exhibited aggrecanase 
activity in  vitro, cleaving aggrecan at sites previously 
identified as targets for different ADAMTSs: ADAMTS1, 
ADAMTS4 and ADAMTS5. Immunodetection of the 
cleaved fragments showed one or more of these enzymes to 
be responsible for the ectosome activity [54].
Ectosomes may promote cancer invasion and metas-
tasis indirectly by altering normal cell function. Through 
interactions with cancer ectosomes, stromal cells such as 
fibroblasts contribute to the creation of a favorable niche 
for cancer development. In studies by Castellana et al. [24], 
fibroblasts were activated in  vitro by ectosomes derived 
from a highly metastatic prostate cancer cell line (P3C). 
After incubation, the fibroblasts exhibited ERK phospho-
rylation and up-regulation of MMP-9. Moreover, the acti-
vated fibroblasts themselves released vesicles which in turn 
were able to boost the invasiveness and migration of P3C 
cells. A similar observation was reported in yet another 
study [55] confirming the role of tumor-derived ectosomes 
in activating stromal cells within the tumor microenviron-
ment in  vivo and in  vitro. Ectosomes released by cancer 
stem cell populations (isolated from renal carcinoma cells) 
activated mesenchymal stromal cells (MCSs) and up-regu-
lated the expression of MMP-1 and MMP-3 in MSCs. Mice 
inoculated with renal carcinoma cells (K1) previously cul-
tured with activated MSCs showed increased tumor growth 
versus the control group. Finally, ectosomes released 
in  vitro by MDA-MB-231 carcinoma cells enhanced col-
lagenase activity in fibroblasts (MCF10a cell line). In that 
case, reorganization of 3D collagen matrices by ectosome-
stimulated fibroblasts was associated with increased FAK 
phosphorylation [56].
Matrix degradation and subsequent tumor invasion have 
also been correlated with elevated expression of uroki-
nase and other components of the plasminogen activation 
system. Schroder et  al. [57] recently demonstrated that 
SerpinB2 (plasminogen activator inhibitor type 2/PAI2) 
is expressed on the surface of ectosomes released by B16 
melanoma cells. SerpinB2-expressing ectosomes signifi-
cantly reduced urokinase (uPA) activity in  vitro as com-
pared with vesicles obtained from control cells that did 
not produce SerpinB2. This mechanism was later used to 
explain the decreased migratory properties of SerpinB2-
expressing B16 cells in Transwell assays, suggesting that 
ectosome-associated SerpinB2 may also inhibit uPA-medi-
ated cancer invasion, migration and metastasis in vivo [57].
Angiogenesis
In the course of carcinogenesis, enlargement of the tumor 
requires expansion of the vascular network. Neovasculari-
zation allows effective delivery of substances essential for 
survival of tumors and facilitates their subsequent migra-
tion to metastatic sites. Initiation of angiogenesis in tumor 
lesions is associated primarily with activation of various 
signaling pathways in tumor cells, leading to prolifera-
tion and migration of vascular endothelial cells or their 
precursors.
Ectosomes released by different cancer cells have been 
shown to facilitate the transfer of several proangiogenic 
factors or to up-regulate their expression in endothelial 
cells. Studies by Taraboletti et  al. [28] demonstrated that 
ectosomes isolated from two ovarian cancer cell lines 
(CABA1, A2780) contained significant amounts of matrix-
degrading metalloproteinases (MMP-2, MMP-9) and 
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vascular epithelium growth factor (VEGF), and that these 
factors stimulated the motility and invasion of endothelial 
cells into Matrigel. In other work, human umbilical cord 
vein cells (HUVECs) showed up-regulated expression 
of autocrine VEGF upon uptake of EGFRvIII from ecto-
somes released by two human epithelial carcinoma cell 
lines (A431, A549) [18]. In another study, induction of 
the angiogenic phenotype in HUVECs was attributed to 
the presence of CD147/EMMPRIN in ectosomes derived 
from three ovarian cancer cell lines (OVCAR3, SKOV3, 
A2780). CD147/EMMPRIN-positive vesicles stimu-
lated in vitro proliferation, invasiveness and expression of 
MMP-2 and MMP-9 in HUVECs [27]. Another proangio-
genic factor is IL-6, whose production (along with VEGF) 
by the EA.hy926 endothelial cell line was increased upon 
incubation with ectosomes derived from human multiple 
myeloma cells. Ectosomes from myeloma cells induced 
proliferation and invasion of EA.hy926 cells, as determined 
in Transwell cell invasion assays [58].
The crucial role of ectosomes in tumor angiogenesis 
has also been confirmed in animal studies. Munster et  al. 
[59] obtained two distinct populations of ectosomes from 
EMT/6 breast cancer cells exposed or not exposed to anti-
VEGF antibody (B20). As expected, mice inoculated with 
ectosomes released by B20-untreated cells showed higher 
mobilization of endothelial precursor cells and their coloni-
zation in growing tumors, as well as increased microvessel 
density [59]. These data suggest that cancer-cell-derived 
ectosomes stimulate the paracrine mechanism of endothe-
lial cell proliferation in both a VEGF-dependent and a 
VEGF-independent manner. However, the most important 
role in cancer neovascularization may well be recognized 
in the endothelial-to-mesenchymal transition (EMT), a 
newly identified type of cellular transdifferentiation respon-
sible for vascular system development and repair [60, 61].
At present, much less is known about the role of mem-
brane lipids transported within ectosomes in tumor angio-
genesis. Kim et  al. [22] identified sphingomyelin in ecto-
somes shed from HT1080 fibrosarcoma cells as the active 
component for ectosome-induced endothelial cell migra-
tion, in  vitro tube formation (Matrigel tube formation 
assay), and ex ovo neovascularization of the chick cho-
rioallantoic membrane; comparable effects on endothe-
lial cell migration and angiogenesis were exerted by lipid 
extracts from ectosomes and purified sphingomyelin, but 
were not observed in the case of lipid extracts previously 
treated with sphingomyelinase [22]. Besides growth fac-
tors, metalloproteinases, cytokines and lipids, ectosomes 
may supply endothelial cells with proangiogenic miRNAs. 
Transfer of pro- and anti-angiogenic miRNA from cancer 
to endothelial cells via ectosomes may promote the forma-
tion of blood vessels by altering the translation of particu-
lar proangiogenic factors, or it may cause down-regulation 
of VEGF expression in a microRNA-specific manner [47, 
62]. Among the different microRNA and protein cargos 
identified in human collateral cancer ectosomes, miR-1246 
and TGF-β have been demonstrated to exert their pro-
angiogenic effects by activating Smad 1/5/8 signaling in 
HUVECs [63].
Another important example of pro-angiogenic cancer 
ectosomes and cell interactions is the contribution of plate-
let-derived microvesicles (PMVs) in carcinogenesis and 
neovascularization [6]. Below we cover what is currently 
known about this.
Cancer‑induced thrombosis
Since cancer progression is often associated with increased 
platelet activation and aggregation, PMVs are thought to 
be mediators in platelet-tumor interactions. Tumor cells 
activate the production of thrombin, a common agonist 
of platelets, which induces ectosome shedding [64]. For 
example, the supernatant obtained from a human neuro-
blastoma cell line (NCG) induced platelet aggregation 
via thrombin-induced procoagulant activity [65]. CD41 
(GPIIb/IIIa, αIIbβ3) and P-selectin are specific antigens 
for activated platelets. Their presence on the surface of 
ectosomes promotes adhesion of cancer cells to the vas-
cular endothelium and facilitates their extravasation [11]. 
Adhesion of platelets and circulating cancer cells is regu-
lated mostly by the ligand-receptor mechanism of PSGL-
1/P-selectin interaction, and the presence of P-selectin on 
the surface of PMPs may facilitate binding of P-selectin-
positive ectosomes to PSGL-1-expressing cancer cells and 
thereby increase cancer invasiveness [11, 66]. P-selectin- 
and PSGL-1-dependent accumulation of circulating PMVs 
in vascular injury foci has been described as an important 
mechanism of ectosome delivery to thrombi and of tissue-
factor-dependent fibrin generation [67].
Among the numerous specific procoagulant molecules, 
tissue factor (TF) is the major initiator of thrombin activa-
tion in blood coagulation pathways. A widely discussed 
question is whether PMVs contain platelet-originated TF, 
or if this activator is incorporated into PMVs due to bind-
ing of TF-positive EVs derived from extravascular cells 
and macrophages to PMVs or platelets, or if TF is de novo 
expressed in activated platelets [68]. It is now commonly 
accepted that two forms of TF are present in the circula-
tory system: full length (flTF) and alternatively spliced 
(asTF) [69]. The extracellular domain of flTF was found 
to initiate coagulation by binding coagulation factor VII 
or its activated form (VIIa) to make a membrane-bound 
complex which activates coagulation factor X. Oncogenic 
transformation caused by the RAS mutation and loss of 
p53 resulted in TF up-regulation [70]. Later it was shown 
that ectosome-mediated transfer of TF between two breast 
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cancer cell lines changed cell TF expression related to their 
aggressiveness potential [71]. Therefore it is highly likely 
that PMVs contribute to the transfer of TF-positive ecto-
somes from macrophages and different populations of can-
cer cells, and that they can facilitate the propagation of TF-
related aggressive phenotypes [11, 16, 71, 72]. TF-bearing 
microvesicles arise from lipid rafts and then fuse with acti-
vated platelets through a PSGL-1-dependent mechanism; 
their shedding was significantly reduced under conditions 
of depleted membrane cholesterol [20, 67]. The molecular 
mechanism for activation of TF and other coagulation fac-
tors also involves PS exposure. Presentation of negatively 
charged PS on the surface of ectosomes is closely related 
to exposure of binding sites for coagulation factors Va, VIII 
and X, which leads to their activation and phosphatidylser-
ine-dependent initiation of coagulation pathways [11].
In contrast to the procoagulatory activity of ectosomes, 
anticoagulation and antimetastatic effects of tumor-derived 
large microvesicles have been reported. Expression of plas-
minogen activator inhibitor type 2/PAI-2 (SERPINB2) 
effectively inhibits urokinase activity, and was associated 
with favorable prognoses [57]. Work by Mezouar et al. [73] 
showed that inhibition of platelet activation with clopi-
dogrel (an anti-platelet agent) in an in vivo mouse model 
prevents P-selectin- and (αvβ1, αvβ3) integrin-mediated 
accumulation of ectosomes at the site of thrombosis. Upon 
treatment with clopidogrel, animals bearing pancreatic 
tumors showed a decrease of tumor growth and metastasis. 
Taken together, these observations indicate that the use of 
anti-platelet drugs may improve the efficacy of anticancer 
therapy and slow the rate of disease progression.
Influence on the immune system
The immune system is well adapted to impede cancer 
progression, although its role remains inessential until 
the accumulated genetic changes are fixed. At that point, 
spontaneous cancer immunity may arise to contain tumor 
growth in early stages of its progression; however, many 
types of cancer cells have developed a number of mecha-
nisms allowing them to evade immune surveillance. Ecto-
somes and other MVs are widely associated with suppres-
sion of the immune response to transformed cells, and 
several theories explaining their role have been proposed 
[36, 74–76].
Numerous studies indicate that tumor-derived ectosomes 
may induce chemotaxis of blood leukocytes. In vitro, ecto-
somes released by pancreatic adenocarcinoma (HPC-4), 
colorectal adenocarcinoma (DeTa) and lung carcinoma 
(A549) cell lines stimulated the chemotactic activity of 
granulocytes, lymphocytes and monocytes. Those results 
were obtained using Transwell chambers and were attrib-
uted to several chemokines (particularly IL-8) transferred 
inside ectosomes [74]. Upon interaction with immune cells, 
ectosomes can interfere with the T-cell response by altering 
the differentiation of antigen-presenting cells, or else can 
inhibit functions of effector cells [36]. For example, Köp-
pler et al. [75] described the immunosuppressive properties 
of ectosomes released in  vitro by the Kato gastric carci-
noma cell line. Incubation with isolated vesicles interfered 
with the activation of monocytes by lipopolysaccharide 
(LPS), resulting in decreased release of tumor necrosis fac-
tor α (TNF-α) and granulocyte macrophage colony-stimu-
lating factor (GM–CSF). Another mechanism was shown 
for ectosomes from melanoma and colon carcinoma cell 
lines [76] that inhibited the differentiation of monocytes to 
antigen-presenting dendritic cells. Moreover, the remaining 
population of monocytes released an immunosuppressive 
cytokine—transforming growth factor β (TGF-β)—which 
inhibited T-cell cytolytic activity.
The immunosuppressive effects exerted by ectosomes 
do not appear to be constant and universal. Vesicles iso-
lated from pancreatic adenocarcinoma (HPC-4), colorectal 
adenocarcinoma (DeTa) and lung carcinoma (A549) cell 
lines induced the production of proinflammatory cytokines 
(TNF-α and IL-12) and reactive oxygen intermediates 
(ROIs) by monocytes [77]. As a result, stimulated mono-
cytes showed significantly increased cytotoxic/cytostatic 
effects on cancer cells in  vitro, as compared with control 
monocytes. Despite the enhancement of the antitumor 
response, increased production of the anti-inflammatory 
cytokine IL-10 was also observed [77]. An explanation for 
such a discrepancy has recently been suggested by another 
study. Ectosomes released by colon cancer cell lines (Caco-
2, SW480, SW620, LoVo) were shown to influence the dif-
ferentiation of monocytes to macrophages, resulting in their 
variable polarization status (M1/M2, proinflammatory/
anti-inflammatory) [78]. The impact of ectosomes on mac-
rophage differentiation and cytokine production depended 
on the timing of the monocytes’ contact with isolated vesi-
cles. Immediate exposure resulted in the highest release of 
IL-10, whereas monocytes incubated with ectosomes on 
the sixth day of culture exhibited the strongest secretion of 
IL-12 and TNF-α (corresponding to the increased fraction 
of proinflammatory M1 monocyte-derived macrophages). 
Macrophages that differentiated after prolonged exposure 
to vesicles (days 0, 3 and 6) secreted the lowest amounts of 
IL-12 and TNF-α, probably due to deactivation of mono-
cytes/macrophages by ectosomal hyaluronan fragments 
[78, 79]. Observations made in the last-mentioned time 
regime most likely reflect the immunosuppressive effect of 
prolonged ectosome exposure during cancer progression 
in vivo.
Interactions of tumor-derived ectosomes with immune 
cells may also indirectly regulate different aspects of can-
cer progression, including angiogenesis. In studies by 
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Baj-Krzyworzeka et al. [74], ectosomes released by pancre-
atic adenocarcinoma (HPC-4), colorectal adenocarcinoma 
(DeTa) and lung carcinoma (A549) cell lines increased 
in vitro secretion of proangiogenic cytokine IL-8 by mono-
cytes. Later the proangiogenic potential of ectosome-
treated monocytes was tested in  vivo in a mouse model. 
Matrigel matrixes containing stimulated or not stimu-
lated monocytes were implanted into NOD-SCID mice 
and excised 7 days later. Hemoglobin content in excised 
Matrigel matrixes showed stronger proangiogenic activ-
ity of monocytes previously incubated with ectosomes 
released by cancer cells [74].
Finally, it is important to note that the majority of com-
prehensive studies have focused on the exosomal fraction 
of microvesicles, so the data on the effects of ectosomes on 
the immune system are still very limited. It is very likely 
that effects attributed to exosomes, such as induction of 
effector cell apoptosis, stimulation of suppressor cell dif-
ferentiation, or loss of antigens essential for recognition by 
NK cells and cytotoxic T-cells [80, 81], can also be exerted 
by ectosomes. Additional studies are needed to shed light 
on this question.
The role of ectosomes of non‑cancer origin
As described in previous sections, ectosomes released by 
cancer cells exert multiple regulatory effects during dif-
ferent stages of cancer progression. An increasing number 
of studies also implicate vesicles derived from non-trans-
formed cells (such as fibroblasts and immune cells) or 
platelets in disease development. For instance, ectosomes 
released by immune cells (isolated from mouse spleen) 
induced migration of hepatocarcinoma (H22) and mela-
noma (B16) cell lines in vitro and hepatic cancer metastasis 
in mouse in  vivo. These observations were related to the 
transfer of integrin αMβ2 (CD11b/CD18) from immune 
cells to ectosomes and then to tumor cells. The use of anti-
bodies against either CD11b or CD18 led to significant 
decreases in ectosome-mediated tumor cell migration and 
metastasis [82]. In other work, ectosomes released in vitro 
by cancer-associated fibroblasts increased the proliferation 
of pancreatic cancer cells (DU145 cell line). Moreover, 
the utilization of lactate in anabolic processes was higher 
when DU145 cells received fibroblast proteins via ecto-
somes in Transwell or coculture conditions, suggesting 
that the acquisition of enzymes of the second step of gly-
colysis (subsequently identified in isolated ectosomes) may 
contribute to the metabolic shift of DU145 cells towards a 
reverse Warburg phenotype, more efficient in highly prolif-
erative conditions [83].
Other reports support the suggestion that ectosomes 
released by platelets and megakaryocytes also contribute 
to cancer progression. They are constitutively produced in 
physiological conditions, though elevated levels of them 
have been observed in patients with various types of can-
cer, frequently correlated with disease stage, the pres-
ence of metastases, or survival [11]. In  vivo and in  vitro 
studies confirmed the involvement of platelet-derived 
vesicles (PMVs) in tumor growth, invasion and angiogen-
esis through interactions with cancer or endothelial cells. 
Janowska-Wieczorek et  al. [10] showed that incubation 
with platelet-derived ectosomes resulted in higher expres-
sion of mRNA for several proangiogenic factors (MMP-
9, VEGF, IL-8, HGF) by different lung cancer cell lines, 
and their increased adhesion to endothelial cells in  vitro. 
Up-regulation of MMP-2 expression and activation of 
selected proliferative signaling pathways was also observed 
in cells cultured in the presence of vesicles. After injec-
tion into mice, cells previously incubated with ectosomes 
induced more lung cancer metastatic foci than control can-
cer cells [10]. A complete characterization of circulating 
EVs in colorectal cancer patients revealed that microvesi-
cles obtained by 15,000×g centrifugation (ectosomes) are 
mostly CD41- and CD61-positive (platelet origin) and may 
act as conveyors of cancer-derived smaller vesicles [13].
Potential clinical applications
The presence of ectosomes in various body fluids points to 
their potential use as biomarkers or prognostic indicators of 
cancer development and progression. Tumor-specific mark-
ers exposed on the surface of ectosomes might serve as 
confirmatory tools during the diagnostic process, whereas 
specific changes in the number of released vesicles or in 
their molecular composition appear to be highly indicative 
of disease stage and treatment efficacy.
Ectosomes are also being studied for possible improve-
ment of clinical outcomes, mainly with regard to inhibi-
tion of the vesiculation process or for drug delivery; both 
strategies may benefit cancer management [8]. The clinical 
applications of ectosomes are still in development; their 
full potential is yet to be realized.
Diagnostic value
Ectosomes generally contribute to the pathogenesis of 
cancer, but some of their unique characteristics can be 
exploited as diagnostic, prognostic and surveillance indi-
cators for cancer patients. Elevated levels of ectosomes as 
compared with those of healthy controls have been detected 
in peripheral blood samples from patients with glioblas-
toma [84], non-small-cell lung carcinoma [85] and multi-
ple myeloma [86]. On the other hand, ectosome levels were 
found to be significantly lower in colorectal carcinoma 
patients; thus, increased vesiculation may not be a universal 
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characteristic of all types of cancer. The variation of ecto-
some release levels has been used to distinguish benign 
tumors from malignant breast [87] and prostate [88] can-
cers. Such differences were not observed between benign 
colorectal disease and colorectal carcinoma [89]. Increased 
plasma levels of ectosome-bearing tissue factor may indi-
cate a highly invasive and poorly differentiated type of pan-
creatic cancer more able to infiltrate peripancreatic vessels 
[90].
A thorough determination of ectosomal molecular status 
may allow detection of specific cancer biomarkers. Ecto-
somes obtained from patients with malignant breast cancer 
exhibited elevated expression of several surface antigens 
(CD66; human epidermal growth factor receptor 2, Her2/
neu; breast cancer resistance protein, BRCP; Hsp27) as 
compared with benign tumors, suggesting their potential 
use as relevant diagnostic markers for malignancy [87]. In 
other work, ectosomes released during progression of colo-
rectal and pancreatic cancers were found to express surface 
glycoproteins such as mucine1 (MUC1), carcinoembryonic 
antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). 
The number of MUC1- and CA19-9-positive vesicles dif-
fered significantly between the two cancer types, with 
MUC1 expression higher in colorectal cancer and CA19-9 
expression higher in pancreatic cancer. Since MUC1 and 
CA19-9 are already being used in histopathology as dif-
ferential markers for digestive system cancers, isolation of 
ectosomes from peripheral blood may obviate the need for 
invasive biopsy procedures in the future [88]. Ectosomes 
found in the blood could also furnish a novel prognostic 
tool to monitor malignant cells in multiple myeloma, where 
elevated numbers of CD138-positive vesicles have been 
correlated with the tumor burden [86].
The diagnostic and prognostic uses of elevated numbers 
of ectosomes, or of the presence of vesicles bearing certain 
molecules, depend on the establishment of proper isolation 
protocols. To gain valid information for clinical practice, 
optimal concentrations of uncontaminated vesicle popula-
tions are required. The several methods of obtaining such 
samples are based on vesicle size or density, or on marker 
expression. In general, ectosomes can be selected by differ-
ential centrifugation, immunoaffinity isolation (adsorption 
to magnetic/non-magnetic microbeads) or size exclusion 
chromatography [91, 92]. Unfortunately, so far no sin-
gle isolation protocol can guarantee complete recovery of 
ectosomes from samples, nor ensure maintenance of their 
native form and function.
Management of multidrug resistance
A number of reports suggest that ectosomes are among 
the critical factors in multidrug resistance (MDR), which 
remains an obstacle in cancer chemotherapy. MDR is 
associated with several mechanisms responsible for com-
promising the effectiveness of different chemotherapeu-
tics. The mechanisms include changes in the rate of drug 
uptake and efflux, altered drug metabolism, decreased 
drug-target complex formation, and enhanced DNA 
repair [93]. MDR cancer cells have already been shown 
to overexpress different transporter proteins involved in 
the efflux of anticancer drugs including P-glycoprotein 
(Pgp), multidrug resistance-associated protein 1 (MRP1) 
and breast cancer resistance protein (BCRP) [94]. Recent 
in  vitro studies demonstrated transference of functional 
Pgp [95, 96] or MRP1 [97] and the mRNAs for both 
proteins [97] via ectosomes released by MDR chronic/
acute myeloid leukemia cells to drug-sensitive cells 
which subsequently acquired MDR phenotypes. Some 
of these transporter proteins are transferred alongside 
CD44, ERM (ezrin, radixin, moesin) protein family and 
cytoskeleton proteins within the ectosomal cargo [31]. 
Ezrin is known to determine Pgp membrane localiza-
tion through cytoskeletal association, as shown in leuke-
mic and breast cancer cells [31, 32]. de Souza et al. [96] 
found that upon incubation with ectosomes bearing dif-
ferent inhibitors of apoptosis proteins (IAPs), drug-sen-
sitive human breast adenocarcinoma (MCF7) and human 
lung carcinoma (A595) cells were more resistant to apop-
tosis when treated with cisplatin or paclitaxel.
Apart from delivering transporter proteins, ectosomes 
may also directly facilitate the expulsion of chemothera-
peutics from tumor cells and promote their survival. Dox-
orubicin-treated MCF7 human breast adenocarcinoma cells 
accumulated and released the drug in shed microvesicles 
[98]. This observation implied that modulatory interven-
tions in the vesiculation process may offer a solution for 
various MDR cases, so studies were carried out later to ver-
ify that suggestion. Jorfi et al. [93]. described in vitro sen-
sitization of pancreatic cancer cells (PC3 cell line) to doc-
etaxel upon treatment with vesiculation-inhibiting calpeptin 
(calpain inhibitor). As a result, 20-fold lower concentra-
tions of docetaxel used in the presence of calpeptin induced 
the same degree of apoptosis in PC3 cells as docetaxel 
alone. Inhibition of ectosome budding similarly improved 
the effectiveness of a combination chemotherapy (docetaxel 
and methotrexate) and also reduced the docetaxel dose 
required to limit tumor growth in mouse in vivo. Another 
study pointed to the therapeutic potential of peptidylargi-
nine deiminases (PADs), a family of enzymes responsible 
for post-translational conversion of protein-bound arginine 
to citrulline [99]. PADs have been associated with deimi-
nation of cellular actin, which in turn rearranges the actin 
cytoskeleton and may facilitate vesiculation. Treatment of 
PC3 cells with chloramidine (PAD inhibitor) significantly 
reduced ectosome release and increased the sensitivity of 
PC3 cells to the cytotoxic effect of methotrexate.
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In contrast to the presented findings, clinical outcomes 
may be improved by stimulation of the vesiculation pro-
cess in certain types of cancer. Different ectosome-releas-
ing agents are considered as potential alternative drugs in, 
for example, differentiation therapy against acute myeloid 
leukemia. Anso-Adda et al. [100] found that promonocytic 
leukemia cells (THA-1) released increased amounts of 
ectosomes upon stimulation with phorbol myristate ace-
tate, all-trans retinoic acid and histamine. Isolated vesicles 
containing TGF-β1 inhibited the proliferation of THA-1 
cells, and they induced differentiation of those cells to 
monocytes/macrophages.
Therapeutic use
Ectosomes can carry a multitude of bioactive molecules. 
Potentially they offer a unique carrier system to deliver dif-
ferent therapeutic agents to cancer cells. Obvious advan-
tages include easy preparation and manipulation, no restric-
tion regarding the physicochemical properties of drugs, and 
the lack of autoimmune reaction due to the autochthonous 
origin of isolated vesicles [101]. Since ectosomes carry a 
variety of cancer-related surface receptors and adhesion 
molecules, they might be easily transported to specific 
tumor sites, enabling local drug delivery.
Recent preclinical and clinical trials have already 
exploited synthetic liposomes to successfully deliver 
chemotherapeutics such as doxorubicin or daunorubicin 
to in  vitro cultures of melanoma cells [102] or in leuke-
mic patients [103, 104]. The observed anticancer effects 
(decreased tumor growth [101] or prolonged survival after 
leukemia relapse [103, 104]) suggest that refinement and 
modification of natural vesiculation processes may allow 
ectosomes to be used as novel therapeutic vehicles. Tang 
et  al. [101] demonstrated that malignant hepatocarcinoma 
cells (H22 cell line) incubated with doxorubicin, cisplatin 
or methotrexate subsequently released drug-containing 
ectosomes. Isolated vesicles had a cytotoxic effect on tumor 
cells in  vitro and reduced hepatocarcinoma and ovarian 
cancer growth in mouse in vivo. Moreover, the ectosome-
encapsulated chemotherapeutic agents showed higher 
efficacy and less adverse effects than drugs administered 
directly.
Ectosomes can also be used as vaccines in cancer man-
agement. In studies by Zhang et  al. [105], 50% of mice 
immunized with ectosomes isolated from hepatocarcinoma 
(H22), melanoma (B16) and colon carcinoma (CT26) cell 
lines remained tumor-free after injection of cancer cells. 
Vesicles from the vaccines were taken up by dendritic cells 
and induced the expression of type-I IFN by activating the 
pathway of the cyclic GMP-AMP synthase/stimulator of 
interferon genes (cGAS/STING). Type-I IFN enhanced the 
maturation of dendritic cells that activated tumor-specific 
T-cells, leading to cytolysis of cancer cells [105, 106]. Only 
12.5% of mice immunized with exosomes released by the 
same cell lines did not develop tumors, suggesting that 
ectosomes are more immunogenic and are a better option 
for developing cancer vaccines [105].
Ran et  al. [107] demonstrated that ectosomes can also 
deliver an oncolytic adenovirus into the nucleus of tumor-
ogenic cells and thus are potential agents for virotherapy. 
The applied vesicles were fatal to tumor cells cultured 
in vitro and also reduced tumor growth in vivo in adeno-
carcinoma mice. Moreover, the cytolytic activity of virus-
containing ectosomes was more efficient than that of a free 
virus, because they appeared to be resistant to virus anti-
bodies. Finally, ectosomes have also been shown to transfer 
miRNAs that regulate target gene expression and functions 
of recipient cells [108, 109]. The use of vesicles contain-
ing particular miRNAs in gene therapy clearly holds great 
promise, but so far no studies involving different models of 
cancer disease have been carried out.
Concluding remarks
In this review we summarized the recent literature on the 
properties and biogenesis of tumor-derived ectosomes, as 
well as their potential roles in cancer growth. Revealing 
their biological roles is only the beginning. This branch 
of research has entered a phase of rapid progress. Tumor-
derived ectosomes are now recognized to play significant 
roles in tumor development, facilitating the spread and 
release of cancer cells to generate metastases. Work on 
ectosomes has shed new light on the pathogenesis of malig-
nant disease. They are a reservoir of biological information 
and a vital component of the specific microenvironment 
of the cell to the tumor microenvironment and to recipient 
cells, tumor-derived ectosomes provide a unique means of 
cellular export and cell-to-cell transport of insoluble bioac-
tive molecules such as nucleic acids, membrane receptors 
and signaling molecules which affect recipient cell metabo-
lism, mRNA processing, cell growth and motility, as well 
as angiogenesis and immune system functioning (Fig.  4). 
Elevated levels of tumor-derived ectosomes are associated 
with a variety of cancers, including brain [84], lung [85], 
breast [87], prostate [88], pancreatic [90] and gastric [108] 
cancers, as well as acute promyelocytic leukemia [110]. As 
it is well established that the number of tumor-derived ecto-
somes increases with cell invasiveness or disease progres-
sion [14], potentially these vesicles can serve as prognostic 
biomarkers of disease stages and of treatment efficacy, and 
can be effective targets for anticancer therapies.
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